Unresectable Or Metastatic Hepatocellular Carcinoma clinical trials

Explore recruiting unresectable or metastatic hepatocellular carcinoma clinical trials.

Recruiting unresectable or metastatic hepatocellular carcinoma studies right now

Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Unresectable Or Metastatic Hepatocellular Carcinoma trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A Phase 2b, Randomized, Blinded Trial Investigating the Efficacy and Safety of Visugromab in combination with Nivolumab and Lenvatinib compared to Double Placebo and Lenvatinib in Participants with Unresectable or Metastatic Hepatocellular Carcinoma and Compensated Liver Function (Child-Pugh A) after Failure of First-Line Treatment that Included an Anti-PD-(L)1 Compound (GDFATHER-HCC-01)

Germany, France, Italy, Spain

Therapeutic exploratory (Phase II) EU CTIS Study details

Unresectable Or Metastatic Hepatocellular Carcinoma trials by city

Unresectable Or Metastatic Hepatocellular Carcinoma clinical trials

Recruiting unresectable or metastatic hepatocellular carcinoma studies right now

FGF19 Overexpression Combination Unified Study in HCC-19

TheraSphere Japan Pre-Market Study

Dual-Target GPC3/B7-H3 CAR-NK Cells for Advanced HCC

Visugromab, Nivolumab and Lenvatinib Compared to Double Placebo and Lenvatinib in Unresectable or Metastatic Hepatocellular Carcinoma Post Anti-PD-(L)1 Failure

Symbiotic-GI-13: A Study to Learn About Study Medicine Called PF-08634404 as a Single Treatment and Combination Treatment in Adult Participants With a Liver Cancer Called Hepatocellular Carcinoma, That is Too Advanced to be Removed by Surgery and May Have Spread to Other Parts of the Body.

Study of RP2 in Combination With Second-line Therapy in Patients With Locally Advanced or Metastatic HCC

Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors

A Study of TTI-101 as Monotherapy and in Combination in Participants With Locally Advanced or Metastatic, and Unresectable Hepatocellular Carcinoma

Study of Zanzalintinib in Combination With Immuno-Oncology Agents in Participants With Solid Tumors

Atezolizumab in Combination With a Multi-Kinase Inhibitor for the Treatment of Unresectable, Locally Advanced, or Metastatic Liver Cancer

A Study to Evaluate the Efficacy and Safety of IBI310 and Sintilimab Combination Therapy in Patients With Hepatocellular Carcinoma as First-line Treatment.

Also recruiting in Europe

Unresectable Or Metastatic Hepatocellular Carcinoma trials by city

Other conditions